Skip to content
LifeSci Partners Podcast cover art

All episodes

LifeSci Partners Podcast, 74 episodes.

#
Title
1

Leveraging AI and ML in Drug R&D: Current and Future Impacts to the Life Sciences Industry

2

LifeSci Search Podcast: Episode #1

3

Regenerative Medicine from Humacyte: Off-the-Shelf, Human-Sourced Acellular Vessels for Traumatic Wound Repair

4

A Brief Chat with Erez Raphael, CEO of DarioHealth

5

Onconova – Developing Best-in-class Anti-cancer Agents with Multi-faceted MOAs

6

A Brief Chat with Dror Bashan, President & CEO of Protalix Biotherapeutics, Inc.

7

A Brief Chat with Martin Welschof, CEO of BioInvent

8

A Brief Chat with Raphi Levy, CFO of Alpha Tau Medical Ltd.

9

A Brief Chat with Amir London, CEO of Kamada Ltd.

10

A Brief Chat with Rob Etherington, President & CEO of Clene, Inc.

11

Helping the Body Help Itself with EscharEx: The Next Generation Wound-Care Therapeutic from MediWound

12

A Promising New Immune Checkpoint from Sensei Bio: VISTA

13

Turning Amino Acids into Drugs: A Novel Platform from Axcella Health

14

Lipocine Inc’s Formulation for Success: Oral Agents for CNS Disorders

15

89bio Aims to Tame NASH and Severe Hypertriglyceridemia (SHTG) with Lead Asset Pegozafermin

16

De-Risked Oncology Targets with Assets from Checkpoint Therapeutics

17

Deep Transcranial Magnetic Stimulation (Deep TMS™): BrainsWay’s Innovative and Non-Invasive Therapy for Major Depressive Disorder, Anxious Depression, OCD, and Smoking Addiction

18

An Oncology Update on CDK 2/9 Inhibition: Cyclacel Pharmaceuticals

19

Oncology on the Move—Artios: Financing Considerations for an Early Biotech

20

Fire Up the Immune System to Lead the Charge Against Cancer: Alligator Bioscience

21

Esperion Therapeutics: A Small Company with a Big Heart

22

Patient-centric, Physician-managed healthcare centers that Payers love: P3 Health Partners

23

Two Oncology Assets in the Clinic and a sought-after Discovery Platform: Ryvu Therapeutics

24

Advances in gene therapy delivery: a non-viral pDNA platform that harnesses the power of IL-10

25

A Pioneer of PARP Inhibition has a New DNA Damage Repair (DDR) Platform

26

Teclison’s cancer immunotherapy-enhancer, TEC-001, shows efficacy in all-cause hepatic tumors

27

iBreathe it in: Inhalable drug delivery with the iSPERSE platform, from Pulmatrix

28

P53 Reactivation via MDM2 Inhibition with Milademetan: Phase 3 Data in 1H 2023 (Rain Therapeutics)

29

An anti-PD-L1 Antibody Given Subcutaneously: Envafolimab, by Tracon Pharma

30

Two conditions, one drug: working to relieve chronic cough in IPF, and debilitating itch in prurigo nodularis with the opioid-receptor-targeting drug, HADUVIO

31

Special Delivery Platforms: pH-activated and STING activating polymeric micelles from OncoNano Medicine

32

Phase II POC for Immutep’s LAG-3 drug, eftilagimod alpha: ASCO data, and an introduction to CEO Marc Voigt

33

Inducing Immune Tolerance in Autoimmunity, Gene Therapy, and Beyond: The ImmTOR® Platform, from Selecta Biosciences

34

Dosing more than Skin Deep: A Transdermal Drug Delivery Platform from Dyve Biosciences

35

Location, Location, Location: Delivering Your IO Asset Directly to the Lymph Node with Amphiphile

36

Making sure there’s not a dry eye in the house with Tyrvaya®, from Oyster Point Pharma

37

The sweet spot (and the market) between the adaptive & innate immune response: Allogeneic Natural Killer T cells (NKT) from Athenex

38

A Rare (Disease) Opportunity: Amolyt Pharma – Targeting Orphan Diseases of the Endocrine System

39

A clinical-stage biotech company developing a targeted oral small molecule for synergistic combinations with SOC -that's Cardiff Oncology.

40

Today’s Oncology Play: Global Reach, Clinical Stage Assets, and a Revenue Stream – Antengene

41

Dyadic International: Helping to produce biologic vaccines and drugs rapidly, in large quantities and at low cost for a global population.

42

Differentiated Delivery with DPX® - a Versatile Technology for Immuno-Oncology by IMV Inc.

43

Developing Drugs for Rare Diseases: Pointers and Pitfalls

44

Targeting Cancer and Fibrosis. Galecto aims to help patients with their first-in-class, small molecule drugs in clinical development

45

Mapping Neoantigens in Cancer with Genocea’s ATLAS: What to Include, and What to Avoid in Your Cancer Therapy

46

Every tumor is a deadly frontier, and to survive it you need a personalized, therapeutic path forward. Enter the AI-centric guidance of Evaxion’s, PIONEER

47

Water, Water, Everywhere – Innovations in Treating Diuretic-Resistant Fluid Overload: Sequana Medical

48

Modulation of NMDA Receptors for Pain and CNS Disorders: The Middle Way – that’s Aptinyx

49

Immatics: Engineering the Right T Cell Receptor for Shared Tumor-Associated Targets

50

Captor Therapeutics: Top Grades for Degrading Pathologic Proteins in Oncology and Autoimmune Disease: Captor Therapeutics

51

Discovery Platform for Small Molecule mRNA Drugs like no other: mRNA Lightning, from Anima Biotech

52

Seeing clearly where the sun don’t shine: A game-changing technology in GI endoscopy from Motus GI

53

GBS Inc: A Saliva Test for Diabetes Monitoring: An inside look at the Glucose Biosensor Technology

54

Lean and mean, outsourcing oncology machine: Anixa Biosciences, Inc.

55

NOXXON: Targeting the Chemokines of the TME to enhance Cancer Therapies

56

Femasys Inc: Putting the Focus on Women’s Reproductive Health

57

To Find the best Antigens for Cancer, or COVID, Gritstone bio has the EDGE™

58

Vincerx Pharma: From Pharmacyclics to Cyclins – The Will and the Way

59

Repairing Organ Damage – Angion Biomedica

60

Experience, Passion, and a Plan: Vera Therapeutics, Dr. Marshall Fordyce takes us from the bedside to the boardroom in his mission to treat autoimmune disease

61

A Promising Repurpose: Tenax Therapeutics Tests the Cancer Drug Imatinib in Pulmonary Arterial Hypertension

62

Medicenna Therapeutics: Reining in the Fire: Taming IL-2?

63

Immutep: No Longer Left Behind: LAG-3 Hits the Clinical (Late) Stage

64

Compugen Pioneering DNAM axis in cancer: TIGIT and PVRIG – Synergistic Checkpoints

65

HERVs and Nerves: Targeting the viral origins of neurodegenerative disease

66

Are iNKT cells the next frontier in cancer treatment?

67

Pixium Vision SA: An Eye Towards the Future: High Tech Treatment for Dry AMD

68

Arcellx: Plug and Play CAR-T: Modular Immunotherapy

69

A Time for Cocktails. Polytope: A Potential Treatment for Covid-19

70

Getting the Bugs out of Alzheimer’s: A New Therapeutic Approach

71

Switching it Up: Medigene Charts a New Course

72

Cancer Treatment Goes Viral Featuring: Dr. Matt Coffey, CEO Oncolytics Biotech

73

BiomX: A Real Phage-Turner

74

NK cell biology no longer stands for “Not Known”: Michael A. Caligiuri, M.D., Chief Medical Officer, and Co-founder of CytoImmune Therapeutics